1 Estimation of SARS-CoV-2 emissions from non-symptomatic cases

2	A.A.Prof. Dr. Michael Riediker ¹ , Dr. Dai-Hua Tsai ^{1,2}
3	1 Swiss Centre for Occupational and Environmental Health, Winterthur, Switzerland
4	2 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of
5	Psychiatry Zurich, University of Zurich, Zurich, Switzerland
6	Key Points
7	Question: How much SARS-CoV-2 virus is released from a case by breathing and coughing,
8	and what is the resulting concentration in a room?
9	Finding: Both, breathing and coughing are predicted to release large numbers of viruses,
10	which can lead to billions of virus copies/m ³ in a poorly ventilated room with a coughing
11	emitter.
12	Meaning: These results may explain the high rate of transmissions and implies the need for
13	strict respiratory protection when people are in the same room with a COVID-19 case.
14	Word counts:
15	Abstract: 272, Manuscript: 1801, Tables: 1, Figures: 3
16	Address for correspondence
17	Michael Riediker
18	michael.riediker@alumni.ethz.ch
19	Swiss Centre for Occupational and Environmental Health (SCOEH)

Binzhofstrasse 87, CH-8404 Winterthur, Switzerland, Note: This preprint reports hew research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

22 Importance: Cases of the coronavirus disease 2019 (COVID-19) with no or mild symptoms 23 were reported to frequently transmit the disease even without direct contact. The severe 24 acute respiratory syndrome virus (SARS-COV-2) was found at very high concentrations in 25 swab and sputum of such cases. 26 **Objective**: We aimed to estimate virus release from such cases into different aerosol sizes by normal breathing and coughing, and what exposure can result from this in a room shared 27 28 with such as case. 29 Data Sources and Model: We combined the size-distribution of exhaled breath aerosols for 30 coughing and normal breathing with viral sputum concentrations as approximation for lung 31 lining liquid to obtain an estimate of emitted virus levels. The resulting emission data fed a 32 single-compartment model of airborne concentrations in a room of 50m³, the size of a small office or medical exam room. 33 34 **Results**: The estimated viral load in aerosols emitted by patients while breathing normally 35 was on average 0.34 copies/cm³ and could go up to 11.5 copies/cm³. The corresponding numbers for coughing patients were 10,900 copies/cm³ and 366,000 copies/cm³, 36 37 respectively, per cough. The resulting concentrations in a room with a coughing emitter 38 were always very high, up to 2.02*10^9 copies/m³. However, also regular breathing aerosol 39 from high emitters was predicted to lead to several thousand copies/ m^3 . 40 **Conclusions and Relevance**: These very high predicted virus concentrations may provide an

explanation why for COVID-19, frequent community transmissions from non-symptomatic
cases and also high infection rates in medical staff in hospital settings were reported. Our
findings suggest that strict respiratory protection is needed when there is a chance to be in

the same room with a patient - whether symptomatic or not - especially if this was for a
prolonged time.

46 Introduction

The novel Coronavirus disease 2019 (COVID-19), emerged in late 2019 in Wuhan, China¹ 47 48 from where it spread to the entire world. COVID-19 is caused by a novel type of Coronavirus, 49 the severe acute respiratory syndrome virus (SARS-COV-2)². The host-receptor for SARS-50 CoV-2 was found to be Angiotensin I converting enzyme 2 (ACE2), which is present in cells of the lungs and airways ³. A large number of patients hospitalized for other reasons and also 51 52 an important proportion of the medical staff contracted COVID-19⁴. This is remarkable given that medical professionals are trained at protecting themselves against infections. Also a 53 54 series of community-transmissions were reported from cases that had no apparent symptoms, some even without direct contact ^{5–8}. Correspondences about the viral load in 55 56 samples from COVID-19 patients having no or only mild symptoms reported very high concentrations of SARS-CoV-2 in swab samples ^{8–10}. This raised the question whether 57 58 transfections could occur via the air.

59 When coughing, humans release thousands of aerosol droplets per cubic-centimeter in the 60 size range of 0.6 to 15 μ m, with the droplet concentration increasing strongly with cough flow rate ¹¹. But also normal breathing will lead to some aerosol production, which is 61 attributed to fluid film rupture in the respiratory bronchioles during inhalation leading to the 62 63 formation of droplets that are released during exhalation ¹². The size of these droplets is mostly below 1 μ m¹³. The mode of droplet generation implies that they consist of lung lining 64 65 liquid including dispersed viruses. Indeed, human volunteers exposed to virus-sized nanoparticles show nano-scaled particles in their exhaled breath ^{14,15}. Also, the described 66

67 size distribution of particles emitted from coughing as well as normal respiration suggests

- that an important proportion of them will be able to remain airborne for many hours in
- 69 turbulent conditions ¹⁶.

70 Objectives

- 71 This study aimed to estimate the cumulative viral load released from COVID-19 patients with
- no to moderate symptoms in different aerosol sizes via respiration and coughing. We then
- vsed this information to make a risk appraisal for the situation of a high emitter that is either
- 74 breathing normally or coughing in a room operated at different air exchange rates. We
- chose a room size that is similar to a medical examination room or an office shared by two
- 76 to three people.

77 Design and Methods

78 Concept:

The release of viruses from individual patients was modeled by first calculating the viral load per exhaled droplets formed during normal breathing and while coughing. The resulting sizedistribution provided an initial estimate of the concentration of SARS-CoV-2 virus copies released by a regularly breathing or coughing patient. This viral emission factor was then fed into a well-mixed one-compartment model to simulate the situation in a closed room with different ventilation air exchange rates.

85 Data sources:

86 Data on the number of viral copies present in sputum was used to estimate the SARS-CoV-2

- 87 viral load present in the lining liquid of respiratory bronchioles in patients ⁹, specifically an
- 88 average of 7*10^6 copies/ml with a maximum of 2.35*10^9 copies/ml (hereafter referred to

as "high emitters"), and 1,000 copies/ml representing a low-virus producing patient ("low
emitters").

91 Exhaled aerosol size distributions and numbers were retrieved from published studies on coughing ¹¹ and healthy persons ¹². Both studies assessed the size-number distribution of 92 freshly emitted aerosols. The concentration of viral copies in each aerosol size was 93 calculated from the volume of the aerosols, the actual count number in each size and the 94 95 above-mentioned virus-load per ml sputum. The viral load in the actual aerosol counts in 96 each aerosol size was then used to calculate the total viral concentration. The cumulative 97 emissions in the PM₁₀ fraction were summed up after applying the standard size fractionation curves ¹⁷ to the aerosol distribution. 98

99 Model:

100 A one-compartment model estimated the virus load concentration C for a perfectly mixed 101 room of volume V_R of 50 m³ with one patient as source, using the following mass-balance 102 (equation 1):

103
$$V_R * \frac{dC}{dt} = c_{PM10} * RR * V_t - \frac{V_R}{ER} * C(t) - \frac{\ln(2) * V_R}{t_{\frac{1}{2}}} * C(t)$$
 (1)

The emission rate was calculated from the concentration c_{PM10}, the viral load in the PM₁₀size range, which are particles collected with a 50% efficiency cut-off at 10 μm aerodynamic diameter; and a respiratory rate of 15 breaths per minute (RR) at a tidal volume of V_t of 500 ml per breath. Air exchange rates (ER) used were 1-, 3-, 10- and 20-times per hour. The virus' half-life t_½ of 1.1 hours was obtained from an experimental study about the persistence of SARS-CoV-2 on surfaces and when airborne ¹⁸, tested by assessing the 50% tissue culture infective dose (TCID₅₀).

- 111 The model for coughing was identical, except that coughing was assumed to happen every
- 112 30 seconds at a volume of 250 ml.
- All statistics and models were calculated using Stata/SE 15.1 (Mac 64-bit Intel, Rev. 03 Feb
- 114 2020, StataCorp, College Station, TX, USA).

115 Results

- **116** Emissions from normal breathing patients
- 117 To estimate the virus emissions from patients breathing normally, we first calculated the
- 118 viral load for the aerosol size distribution. Figure 1 shows that the highest virus load is
- 119 present in the largest aerosol size. The cumulative total emission per breath was 0.34
- 120 copies/cm³(air) for an average patient, and 11.5 copies/cm³ for high emitters. The
- 121 cumulative emissions in the PM₁₀ fraction were about 1/3 of these values with 0.12
- 122 copies/cm³ (average) and 4.1 copies/cm³ (high) per breath.

123 Emission from coughing patient

- 124 We then estimated the virus emissions from a coughing patient (Figure 2). The cumulative
- total emission per cough was 19,400 copies/cm³ for an average patient, and 651,315
- 126 copies/cm³ for high emitters. The cumulative emissions in the PM₁₀ fraction were about 1/2
- 127 of these values with 10,900 copies/cm³ (average) and 366,000 copies/cm³ (high) per cough.

128 Exposure estimation for bystanders

- 129 To estimate the exposure of bystanders spending time in the same room as a COVID-19
- 130 positive person, we calculated the time-course of the viral load in the thoracic size fraction
- 131 for aerosols released from a high-emitter either breathing normally or coughing. Figure 3
- 132 shows the results for a high-emitting patient coughing frequently.

For a typical hospital ventilation situation of 10 air exchanges per hour, the concentration
plateaus after about 30 minutes, while for a typical office with 3 air exchanges/hour,
concentrations continue to rise for almost three hours. In the used model, concentrations
scale linearly with the patient emission rate, the plateau concentrations for different
emitting patients and ventilation types are summarized in Table 1.

138 Discussion

An elevated number of viruses is expected to be released by COIVD-19 patients in the form of airborne aerosols, especially when they are coughing. While the bigger portion of the emitted viral load is in the form of large particles that can deposit rapidly, there is also an important portion in the smaller size fractions. Small aerosols can remain airborne for an extended time ¹⁶ and are very effective at reaching the deeper regions of the lungs.

144 An average person breathes about a half m³ per hour in resting state ¹⁹, which can rapidly increase to several m³ during exercise ²⁰. Thus, a person spending time in a room with an 145 146 average emitting patient breathing normally has a realistic chance of inhaling tens to 147 hundreds of copies of the virus even when keeping distance from that person. The situation 148 is worse in the presence of a high emitter and worst if the patient is a coughing high emitter. 149 A review of a wide range of respiratory viruses suggests that the infective dose is often quite low. Sometimes as few as few hundred units of active virus (TCID₅₀)²¹ seem sufficient to 150 151 provoke a disease. Thus, our modelling suggests that there is a clear risk of infections for a 152 person spending an extended time in the room with an infected person, even if the distance 153 is too large for direct transmission. The situation is worse if the person is coughing. 154 The very high virus load in exhaled respiratory aerosols proposed by our assessment may be

an explanation why COVID-19 was associated with much more transfections to hospital staff

156	than what was expected from SARS ⁴ . While having everybody wear a surgical face mask can					
157	be an effective source control ²² , the protective factors may still be insufficient if an					
158	extended amount of time is spent in the same room, especially if the room is small and the					
159	ventilation low. Increasing ventilation can help to some extent but is not sufficient in a room					
160	of the size of a typical office or medical exam room. Note also that ventilation design for					
161	hospitals is complex and not always functioning as intended ²³ .					
162	What are the implications for the normal life and the workplace?					
163	• The risk of infection is real when being near an infected person in a room for more					
164	than a few minutes and this even when keeping distance to that person.					
165	• Sharing a workplace in a small room with a non-symptomatic case seems not					
166	advised. This implies that workplaces should not be shared as long as there are no					
167	rapid tests to differentiate between healthy and non-symptomatic cases.					
168	Medical staff is advised to wear the best possible respiratory protection whenever in					
169	the same room as a patient, especially when this person is coughing.					
170	• In addition, every patient, also non-symptomatic ones, should wear a well-fitting					
171	surgical face mask to reduce emissions, which will increase the overall protection for					
172	the medical staff.					
173	Our assessment has a number of limitations. Namely:					
174	• The estimated virus levels strongly depend on the number of virus copies produced					
175	by a COVID-19 case. We used sputum data from a well described peer-reviewed					
176	study ⁹ assuming that it is a reasonable approximation for the virus load in the					
177	respiratory bronchioles, the space where most respiratory aerosols are formed. Our					

178 high-emitter estimates would be 100-fold higher if the most extreme

179 correspondence data was used ¹⁰.

- We used information about virus copies but compare the results with TCID₅₀ infective
 dose. Research on other virus types suggests that the number of virus copies and
 TCID₅₀ are comparable ²⁴. However, it would be important to confirm this
- 183 relationship for the case of SARS-CoV-2.
- For breath aerosols release, we used data reported for normal breathing young
- 185 healthy subjects. However, aerosol formation is influenced by surface tension of the
- 186 lung lining liquid ²⁵. It is likely that aerosol formation will be altered in COVID-19
- 187 positive cases but it is not clear in which direction.
- Aerosol droplet will shrink in dry air ²⁶, resulting in a shift to smaller particle sizes.
- 189 This will not directly change the number of copies in the PM₁₀ range but simply
- 190 upconcentrate the viral load per aerosol. While we addressed passivation of viruses
- 191 in the air by using the documented half-life ¹⁸, it is still possible that viruses in smaller
- 192 droplets are quicker passivated because of shorter diffusion distances for airborne
- 193 oxidants and faster increasing salinity. Our estimates would be slightly smaller if this
- 194 was relevant.

195 Acknowledgments

This modelling was entirely funded by the Swiss Centre for Occupational and EnvironmentalHealth (SCOEH).

198 References

199	•	1.	Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with				
200		Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.					
201		doi:10.1	056/NEJMoa2001017				
202	•	2.	Gorbalenya AE, Baker SC, Baric RS, et al. Severe Acute Respiratory Syndrome-				
203		Related	Coronavirus: The Species and Its Viruses – a Statement of the Coronavirus Study				
204		Group. N	Aicrobiology; 2020. doi:10.1101/2020.02.07.937862				
205	•	3.	Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues				
206		identify	cell types and receptors of human coronaviruses. Biochem Biophys Res				
207		Commui	n. March 2020:S0006291X20305234. doi:10.1016/j.bbrc.2020.03.044				
208	•	4.	Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients				
209		With 20	19 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA.				
210		2020;32	3(11):1061. doi:10.1001/jama.2020.1585				
211	•	5.	Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of				
212		COVID-1	9. <i>JAMA</i> . February 2020. doi:10.1001/jama.2020.2565				
213	•	6.	Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic				
214		SARS-Co	V-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King				
215		County,	Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377-				
216		381. doi	:10.15585/mmwr.mm6913e1				

217	•	7.	Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the				
218		rapid dissemination of novel coronavirus (SARS-CoV2). Science. March 2020.					
219		doi:10.1	126/science.abb3221				
220	•	8.	Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory				
221		Specime	ens of Infected Patients. N Engl J Med. 2020;382(12):1177-1179.				
222		doi:10.1	056/NEJMc2001737				
223	•	9.	Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of				
224		hospital	ized patients with COVID-2019. Nature. April 2020. doi:10.1038/s41586-020-				
225		2196-x					
226	•	10.	Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical				
227		samples	. Lancet Infect Dis. 2020;20(4):411-412. doi:10.1016/S1473-3099(20)30113-4				
228	•	11.	Yang S, Lee GWM, Chen C-M, Wu C-C, Yu K-P. The Size and Concentration of				
229		Droplets	s Generated by Coughing in Human Subjects. J Aerosol Med. 2007;20(4):484-				
230		494. doi	:10.1089/jam.2007.0610				
231	•	12.	Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. J				
232		Aerosol	Med Pulm Drug Deliv. 2009;22(3):229-237. doi:10.1089/jamp.2008.0720				
233	•	13.	Papineni RS, Rosenthal FS. The Size Distribution of Droplets in the Exhaled				
234		Breath c	of Healthy Human Subjects. J Aerosol Med. 1997;10(2):105-116.				
235		doi:10.1	089/jam.1997.10.105				

- 14. Gschwind S, Graczyk H, Günther D, Riediker M. A method for the preservation
- and determination of welding fume nanoparticles in exhaled breath condensate. *Env*
- 238 Sci Nano. 2016;3(2):357–364. doi:10.1039/C5EN00240K
- 15. Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath
- 240 condensate as a matrix for combustion-based nanoparticle exposure and health effect
- evaluation. J Aerosol Med Pulm Drug Deliv. 2014;27(6):449–458.
- 242 doi:10.1089/jamp.2013.1101
- 16. Willeke K, Baron PA, eds. *Aerosol Measurement: Principles, Techniques, and*
- 244 *Applications*. New York: Van Nostrand Reinhold; 1993.
- 17. BSI. EN 481:1993 Workplace Atmospheres. Size Fraction Definitions for
- 246 *Measurement of Airborne Particles*. BSI; 1993.
- 18. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability
- 248 of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. March
- 249 2020:NEJMc2004973. doi:10.1056/NEJMc2004973
- 19. Beardsell I, ed. *Get through MCEM. Part A: MCQs*. London: RSM; 2011.
- 20. Ramos CA, Reis JF, Almeida T, Alves F, Wolterbeek HT, Almeida SM. Estimating
- the inhaled dose of pollutants during indoor physical activity. *Sci Total Environ*.
- 253 2015;527-528:111-118. doi:10.1016/j.scitotenv.2015.04.120
- 21. Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory
- and Enteric Viruses Transmitted Through Food and the Environment. *Food Environ*
- 256 Virol. 2011;3(1):1-30. doi:10.1007/s12560-011-9056-7

- 22. Patel RB, Skaria SD, Mansour MM, Smaldone GC. Respiratory source control
- using a surgical mask: An *in vitro* study. *J Occup Environ Hyg*. 2016;13(7):569-576.
- doi:10.1080/15459624.2015.1043050
- 23. Grosskopf KR, Herstein KR. The aerodynamic behavior of respiratory aerosols
 within a general patient room. 2012;18(4):15.
- 24. Kim J-O, Kim W-S, Kim S-W, et al. Development and Application of
- 263 Quantitative Detection Method for Viral Hemorrhagic Septicemia Virus (VHSV)
- 264 Genogroup IVa. Viruses. 2014;6(5):2204-2213. doi:10.3390/v6052204
- 25. Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols.
- 266 *Proc Natl Acad Sci.* 2004;101(50):17383-17388. doi:10.1073/pnas.0408159101
- e 26. Holmgren H, Bake B, Olin A-C, Ljungström E. Relation Between Humidity and
- Size of Exhaled Particles. *J Aerosol Med Pulm Drug Deliv*. 2011;24(5):253-260.
- 269 doi:10.1089/jamp.2011.0880

270

271 Figure legends

Figure 1: Size distribution of exhaled aerosols (left) during normal respiration and resulting
viral emissions per breath (right) for average (red), high and low emitters (spike-lines) per
aerosol size.

275 Figure 2: Size distribution of exhaled aerosols (left) during coughing and resulting viral

276 emissions per breath (right) with average (red), high and low emitters (spike-lines) per

aerosol size.

- 278 Figure 3: Temporal course of airborne virus load in a perfectly mixed room of 50 m3 for
- 279 different air exchange rates. The emitter has a high virus-load in the lungs and is coughing
- 280 intermittently.

281 Tables

282 Table 1: Plateau concentration for different combinations of air exchange rate, emission form and emitter type.

Air exchange rate (times/	1 / hour	3 / hour	10 / hour	20 / hour			
hour)							
Time until 99% of plateau	169 minutes	77 minutes	26 minutes	14 minutes			
	Airborne viral concentration at plateau (copies/m ³)						
Regular breathing							
Low emitter	0.0096	0.0043	0.0015	0.0008			
Average emitter	44.80	20.18	6.87	3.54			
High emitter	22,554	10,100	3,458	1,782			
Frequent coughing							
Low emitter	859	386	132	67.9			
Average emitter	4,010,000	1,800,000	615,000	317,000			
High emitter	2.02e+09	9.06e+08	3.10e+08	1.60e+08			

283





